In contrast, SGLT-2i and GLP-1 receptor agonists (GLP-1RA) have shown significant reductions in major cardiovascular events, mortality, and HF hospitalization compared to insulin, with better safety profiles [59]. This evidence concerns the gene GLP1R and hydrops fetalis.